Literature DB >> 29637585

Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection.

L Kuhnhenn1,2, B Jiang2, A Kubesch1, J Vermehren1, V Knop1, S Susser1, J Dietz1, G Carra2, F Finkelmeier1, G Grammatikos1, S Zeuzem1, C Sarrazin1,3, E Hildt2,4, K-H Peiffer1,2.   

Abstract

BACKGROUND: HBV DNA and quantitative (q)HBsAg levels as prognostic markers for HBV-related disease are mostly validated in Asia and their significance in Western populations is uncertain. AIM: To analyse the impact of the HBV genotype and frequent mutations in precore (PC), basal core promoter (BCP) and preS on HBV DNA and qHBsAg levels.
METHODS: HBV DNA and qHBsAg serum levels of 465 patients with HBeAg-negative chronic HBV infection were correlated with the HBV genotype and mutations in PC, BCP and preS. For a detailed analysis of the molecular virology, genotype A2 genomes harbouring these mutations were analysed for replication efficacy and HBsAg release in cell culture.
RESULTS: While no impact of the HBV genotype on HBV DNA levels was observed, qHBsAg levels differed up to 1.4 log among the genotypes (P < 0.001), reflected by large differences regarding the 1000 IU/mL HBsAg cut-off. While PC mutations were associated with higher (P < 0.001), BCP mutations were associated with lower HBV DNA levels (P < 0.001). Higher qHBsAg levels were associated with preS and lower levels with PC mutations (P < 0.001 and P = 0.001, respectively). The cell culture experiments revealed a higher HBsAg release and shorter filaments in case of a HBV genome harbouring a preS deletion. In contrast, a perinuclear HBsAg accumulation was detected for the PC and BCP-variants, reflecting an impaired HBsAg release.
CONCLUSIONS: qHBsAg serum levels depend on the HBV genotype and together with HBV DNA levels on frequent mutations in PC, BCP and preS in HBeAg-negative patients. qHBsAg cut-offs when used as prognostic markers require genotype-dependent validation.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29637585     DOI: 10.1111/apt.14636

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Serological and virological response in patients with hepatitis B virus genotype E treated with entecavir or tenofovir: a prospective study.

Authors:  Lucio Boglione; Ilaria De Benedetto; Tommaso Lupia; Jessica Cusato; Giuseppe Cariti; Giovanni Di Perri
Journal:  Arch Virol       Date:  2021-02-12       Impact factor: 2.574

2.  Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection.

Authors:  Pierre Gantner; Laurent Cotte; Clotilde Allavena; Firouzé Bani-Sadr; Thomas Huleux; Claudine Duvivier; Marc-Antoine Valantin; Christine Jacomet; Véronique Joly; Antoine Chéret; Pascal Pugliese; Pierre Delobel; André Cabié; David Rey
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

3.  Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection.

Authors:  Romina Salpini; Arianna Battisti; Lorenzo Piermatteo; Luca Carioti; Olympia E Anastasiou; Upkar S Gill; Domenico Di Carlo; Luna Colagrossi; Leonardo Duca; Ada Bertoli; Katia Yu La Rosa; Lavinia Fabeni; Alessandra Iuvara; Vincenzo Malagnino; Carlotta Cerva; Miriam Lichtner; Claudio M Mastroianni; Giuseppe Maria De Sanctis; Maurizio Paoloni; Massimo Marignani; Caterina Pasquazzi; Nerio Iapadre; Giustino Parruti; Jacopo Vecchiet; Loredana Sarmati; Massimo Andreoni; Mario Angelico; Sandro Grelli; Patrick T Kennedy; Jens Verheyen; Stefano Aquaro; Francesca Ceccherini Silberstein; Carlo Federico Perno; Valentina Svicher
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

4.  Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.

Authors:  Ana Isabel Gil-García; Antonio Madejón; Irene Francisco-Recuero; Ana López-López; Emiliana Villafranca; Miriam Romero; Araceli García; Antonio Olveira; Rocío Mena; Juan Ramón Larrubia; Javier García-Samaniego
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

5.  The N-Terminus Makes the Difference: Impact of Genotype-Specific Disparities in the N-Terminal Part of The Hepatitis B Virus Large Surface Protein on Morphogenesis of Viral and Subviral Particles.

Authors:  Bingfu Jiang; Xingjian Wen; Qingyan Wu; Daniela Bender; Gert Carra; Michael Basic; Alica Kubesch; Kai-Henrik Peiffer; Klaus Boller; Eberhard Hildt
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

6.  Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients.

Authors:  Xiaoqin Lai; Wenfa Chen; Yuzhu Wu; Yali Gao; Yalan Zhang; Xuwei Xu; Ya Fu; Xinwen Wang; Yanbing Yang; Yin Zhang
Journal:  J Clin Lab Anal       Date:  2022-06-03       Impact factor: 3.124

7.  A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype.

Authors:  Sébastien Eymieux; Christophe Hourioux; Julien Marlet; Alain Moreau; Romuald Patient; Louis d'Alteroche; Catherine Gaudy-Graffin; Emmanuelle Blanchard; Philippe Roingeard
Journal:  J Viral Hepat       Date:  2022-06-07       Impact factor: 3.517

8.  Virological activity in treatment-naïve HBeAg-negative HBV-infected adult patients: A community-based study in Jiangsu, China.

Authors:  Xiangjun Zhai; Liguo Zhu; Jie Jiang; Ci Song; Hong Peng; Jiao Qian; MingHao Zhou; Yan Zhou; Qungang Wang; Jianfang Xu; Zhijian Wang; Hongjian Liu; Min Fan; Zhibin Hu; Hongbin Shen; Fengcai Zhu
Journal:  Medicine (Baltimore)       Date:  2020-07-17       Impact factor: 1.817

9.  Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers.

Authors:  Kai-Henrik Peiffer; Catrina Spengler; Michael Basic; Bingfu Jiang; Lisa Kuhnhenn; Wiebke Obermann; Tobias Zahn; Mirco Glitscher; Alessandro Loglio; Floriana Facchetti; Gert Carra; Alica Kubesch; Johannes Vermehren; Viola Knop; Christiana Graf; Julia Dietz; Fabian Finkelmeier; Eva Herrmann; Jonel Trebicka; Arnold Grünweller; Stefan Zeuzem; Christoph Sarrazin; Pietro Lampertico; Eberhard Hildt
Journal:  JCI Insight       Date:  2020-11-19

Review 10.  Viral hepatitis update: Progress and perspectives.

Authors:  María B Pisano; Cecilia G Giadans; Diego M Flichman; Viviana E Ré; María V Preciado; Pamela Valva
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.